Immunotech Laboratories, Inc.
IMMB - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$114.99K
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $114,993.00 |
|---|---|
| Enterprise Value | $2.52 Million |
| Earnings per Share | $0 |
| Beta | -5.14 |
| Outstanding Shares | 576,964,967 |
Return
| Return on Equity | -13.34% |
|---|---|
| Return on Assets | -6.08% |
| Return on Invested Capital | -7.54% |
Valuation & Multiples
| P/E Ratio | -0.22 |
|---|---|
| PEG | 1.05 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -5.18 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.96 |
| Debt to Equity | 0.5 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Immunotech Laboratories, Inc.
4 employees
CEO: Jennifer L. Bath
Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagshi...